Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The histone lysine-specific demethylase inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing ferroptosis.

ABSTRACT: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with various molecular and cytogenetic subtypes. Treatment options for elderly patients are limited due to high toxicity of conventional chemotherapy. The BCL-2 inhibitor venetoclax is effective in combination with hypomethylating agents or low-dose cytarabine, but about 30% of patients don’t respond to the initial combination treatment. Thus, alternative combinations are needed to sensitize AML cells to venetoclax and overcome resistance mechanisms. Here, we report that targeting histone lysine-specific demethylases (KDMs) induces ferroptosis in various AML subtypes. In both patient samples and cell lines, JIB04 increases the level of reactive oxygen species (ROS), ferrous iron, and lipid peroxidation, all signs of ferroptosis. The combination of JIB04 and venetoclax proved to be highly synergistic and was dependent on ferroptosis induction. Blocking ferroptosis by using the antioxidant N-Acetyl-L-cysteine (NAC) reverses the synergistic killing. On the molecular level, the ferroptosis inducers HMOX1, SAT1, and PTGS2 were found to be upregulated by JIB04. Collectively, these findings identify JIB04 as a new ferroptosis inducer in AML and highlight the potential of ferroptosis induction as a valuable strategy in combination with venetoclax to treat AML.

ORGANISM(S): Homo sapiens

PROVIDER: GSE294417 | GEO | 2026/06/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The histone lysine-specific demethylase inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing ferroptosis [RNA-seq]

Project description:Acute myeloid leukemia (AML) is an aggressive hematological malignancy with various molecular and cytogenetic subtypes. Treatment options for elderly patients are limited due to high toxicity of conventional chemotherapy. The BCL-2 inhibitor venetoclax is effective in combination with hypomethylating agents or low-dose cytarabine, but about 30% of patients don’t respond to the initial combination treatment. Thus, alternative combinations are needed to sensitize AML cells to venetoclax and overcome resistance mechanisms. Here, we report that targeting histone lysine-specific demethylases (KDMs) induces ferroptosis in various AML subtypes. In both patient samples and cell lines, JIB04 increases the level of reactive oxygen species (ROS), ferrous iron, and lipid peroxidation, all signs of ferroptosis. The combination of JIB04 and venetoclax proved to be highly synergistic and was dependent on ferroptosis induction. Blocking ferroptosis by using the antioxidant N-Acetyl-L-cysteine (NAC) reverses the synergistic killing. On the molecular level, the ferroptosis inducers HMOX1, SAT1, and PTGS2 were found to be upregulated by JIB04. Collectively, these findings identify JIB04 as a new ferroptosis inducer in AML and highlight the potential of ferroptosis induction as a valuable strategy in combination with venetoclax to treat AML.

2026-06-03 | GSE294425 | GEO

Paired single-cell RNA-seq pre- and post-venetoclax therapy of 8 AML patients

Project description:Acute myeloid leukemia (AML) remains a cancer with dismal prognosis, particularly in high-risk disease patients and those ineligible for allogeneic stem cell transplantation. BCL-2 inhibitor venetoclax, in combination with hypomethylating agents, has emerged as an effective therapy and forms the backbone of multiple combination therapies in clinical trials. However, venetoclax-based therapy is rarely curative. While multiple venetoclax resistance mechanisms have been discovered, most of these have been identified using cell line models that only partially reflect the heterogeneous composition of human AML. Using paired single-cell data from 8 AML patients with pre- and post-venetoclax therapy samples, we aimed to characterize mechanisms driving venetoclax resistance in a clinically relevant setting.

2025-12-31 | E-MTAB-14143 | biostudies-arrayexpress

The histone lysine-specific demethylase inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing ferroptosis.

Project description:The histone lysine-specific demethylase inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing ferroptosis.

| PRJNA1249421 | ENA

The histone lysine-specific demethylase inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing ferroptosis [RNA-seq]

Project description:The histone lysine-specific demethylase inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing ferroptosis [RNA-seq]

| PRJNA1249428 | ENA

Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax

Project description:The With-No-Lysine (WNK) kinase family plays critical roles in cellular signaling, yet its significance in acute myeloid leukemia (AML) remains unclear. Here, we demonstrate that WNK1 is a novel therapeutic target in AML. Analysis of public databases and primary patient samples reveals that WNK1, but not other WNK family members, is highly expressed in AML, particularly in adverse subtypes such as FLT3-ITD mutated AML. CRISPR dependency scores confirm WNK1 is essential for AML cell survival. Pharmacological inhibition of WNK1 using WNK463 or WNK11 significantly suppresses the proliferation of AML cell lines and primary blasts, induces apoptosis through upregulation of pro-apoptotic proteins Bim and Puma, and impedes tumor growth in mouse xenograft models without significant toxicity. Transcriptomic analysis indicates that WNK1 inhibition downregulates genes involved in DNA replication pathways, including MCM5, CHAF1B, and GINS2, whose high expression correlates with poor prognosis. Importantly, elevated WNK1 expression is associated with resistance to the BCL-2 inhibitor venetoclax, a frontline AML therapy. Combining WNK463 with venetoclax exhibits synergistic anti-leukemic effects in vitro, accompanied by enhanced Bim upregulation. In summary, our study identifies WNK1 as a key oncogenic driver in AML and establishes WNK1 inhibition as a promising therapeutic strategy that suppresses AML progression and sensitizes leukemia cells to venetoclax, providing a rationale for novel combination regimens to overcome drug resistance.

2026-05-29 | GSE333251 | GEO

A novel covalent inhibitor of CDK7 synergizes with Venetoclax in acute myeloid leukemia

Project description:To assess the synergistic effects of CDK7 inhibitor with Venetoclax, we performed RNA sequencing and gene set enrichment analysis using Venetoclax sensitive and resistant model systems. RNA-sequencing from paired Venetoclax-sensitive and Venetoclax-resistant cells treated with CDK7 inhibitor showed downregulation of genes involved in proliferation and apoptosis. CDK7 inhibitor induces apoptosis in AML cells and combined treatment with Venetoclax led to synergistic effects in overcoming resistance.

2023-07-24 | GSE231745 | GEO

Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2 [scRNA-seq]

Project description:Majority of RUNX1 mutations in AML are missense or deletion-truncation and behave as loss-of-function mutations. Following standard therapy, AML patients expressing mtRUNX1 exhibit inferior clinical outcome than those without mutant RUNX1. Studies presented here demonstrate that as compared to AML cells lacking mtRUNX1, their isogenic counterparts harboring mtRUNX1 display impaired ribosomal biogenesis and differentiation, as well as exhibit reduced levels of wild-type RUNX1, PU.1 and c-Myc. Compared to AML cells with only wild-type RUNX1, AML cells expressing mtRUNX1 were also more sensitive to the protein translation inhibitor homoharringtonine (omacetaxine) and BCL2 inhibitor venetoclax. HHT treatment repressed enhancers and their BRD4 occupancy, as well as reduced levels of c-Myc, c-Myb, MCL1 and Bcl-xL. Consistent with this, co-treatment with omacetaxine and venetoclax or BET inhibitor induced synergistic in vitro lethality in AML expressing mtRUNX1. Compared to each agent alone, co-treatment with omacetaxine and venetoclax or BET inhibitor also displayed improved in vivo anti-AML efficacy, associated with improved survival of immune depleted mice engrafted with AML cells harboring mtRUNX1. These findings highlight superior efficacy of omacetaxine-based combination therapies for AML harboring mtRUNX1.

2022-04-09 | GSE182020 | GEO

Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2 [RNA-seq]

2022-04-09 | GSE182018 | GEO

Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2 [ChIP-seq]

2022-04-09 | GSE182006 | GEO

Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2 [ATAC-seq]

2022-04-09 | GSE181977 | GEO